Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2001

View Archived Issues

Water-soluble MMP inhibitors with potent, broad-spectrum activity

Ro-0098557: a development candidate with strong parenteral and oral antifungal activity in rats

Active Biotech signs benzamide licensing agreement with Oxigene

European Commission extends pramipexole's indications to include initial monotherapy

DGI BioTechnologies receives milestone payment for role in discovery of mimics of insulin

OncoGenex and Isis collaborate on antisense drug for prostate and other cancers

Potent TNF-alpha inhibitor selected as potential antiarthritic agent at Sumitomo

Initial phase I study for HE-2200 completed; clearance given for further study

Antiapoptotic agents targeting caspase 3 designed by Yamanouchi, presented in Kyoto

Promising antifibrillatory profile described this week in Kyoto for new piperidine derivative

Synthesis and antibacterial activity of alpha-substituted acylides presented by Taisho group

Preclinical profile of new NK1 antagonist suggests potential in emesis and depression

RARalpha-selective agonist undergoes early clinical testing in cancer patients

Two-year extension to Pharmacopeia and Otsuka collaboration

Phase II trial of GVAX cancer vaccine for acute myelogenous leukemia set to commence

Exelixis delivers further cancer targets to Protein Design Labs

FDA approves expanded use of Myoview

NDA submission for Alprox-TD in Singapore

Adenovirus-mediated PTEN gene transfer effective against human colorectal cancer

Orphan drug status granted for IL-13-PE38 for the treatment of malignant glioma

Pyrrolopyrimidine tyrosine kinase inhibitors claimed by BASF

Lilly compounds acting as kainate receptor antagonists specifically claimed for epilepsy

TNF-alpha production inhibitors and potential uses thereof described by Chugai

Novel therapeutic agents for schizophrenia and anxiety designed at Knoll

AstraZeneca presents CDK inhibitors in recent patent

Estrogen receptor modulators reported by Akzo Nobel scientists

Boehringer Ingelheim synthesizes compounds useful for inhibiting IL-2 production

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...